The New England Journal of Medicine » COPD
1 FOLLOWERS
The Copd page contains articles and information from the New England Journal of Medicine on COPD, research, treatments and more! The New England Journal of Medicine (NEJM) is recognized as the world's leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed research and interactive clinical content to physicians, educators,..
The New England Journal of Medicine » COPD
2M ago
Collaboration between the FDA and other stakeholders could improve the way in which evidence is generated and interventions are developed and implemented to help address common chronic diseases ..read more
The New England Journal of Medicine » COPD
2M ago
The use of biologic therapies, including monoclonal antibodies, has revolutionized the treatment of many human diseases. In respiratory medicine, monoclonal antibodies have already transformed the management of severe asthma. By contrast, previous trials of biologic agents targeting interleukin-5 have yielded potentially relevant but mostly inconclusive results in patients ..read more
The New England Journal of Medicine » COPD
9M ago
The use of biologic therapies, including monoclonal antibodies, has revolutionized the treatment of many human diseases. In respiratory medicine, monoclonal antibodies have already transformed the management of severe asthma. By contrast, previous trials of biologic agents targeting interleukin-5 have yielded potentially relevant but mostly inconclusive results in patients ..read more
The New England Journal of Medicine » COPD
10M ago
In this randomized trial, dupilumab resulted in a lower annualized rate of exacerbations than placebo among patients with COPD and an elevated blood eosinophil count ..read more
The New England Journal of Medicine » COPD
10M ago
HFCs were introduced as ozone-friendly substitutes for chlorofluorocarbons, but they, too, are greenhouse gases. The use of HFCs in insulation, refrigeration, and aerosols must be phased down quickly ..read more
The New England Journal of Medicine » COPD
11M ago
The Procalcitonin Antibiotic Consensus Trial (ProACT) showed that a procalcitonin-guided antibiotic prescription guideline did not improve 30-day outcomes among patients with suspected lower respiratory tract infection. The investigators have now assessed mortality at 90 and 365 days and again found no evidence of benefit ..read more
The New England Journal of Medicine » COPD
11M ago
This study from the CDC compared the characteristics of 60 patients who died from EVALI with those of 2558 patients who were hospitalized for the condition but survived. The deaths were reported from 27 states and the District of Columbia, and most were associated with vaping THC-containing products before symptom ..read more
The New England Journal of Medicine » COPD
11M ago
In Ireland, augmentation treatment of patients with genetic alpha -antitrypsin deficiency was abruptly discontinued when government–industry price negotiations failed. After treatment was stopped, the incidence of hospitalization for COPD and mortality exceeded those observed while treatment was ongoing ..read more
The New England Journal of Medicine » COPD
11M ago
Patients with COPD were randomly assigned to triple inhaled therapy with either a 160-μg or 320-μg dose of budesonide or to one of two dual therapies. Both triple regimens were superior to the dual regimens with respect to the rate of moderate or severe exacerbations; no difference was observed between ..read more
The New England Journal of Medicine » COPD
11M ago
The patient-safety movement has turned clinical medicine into a team sport, but administrators have been left off the team. The effects on patients of administrative decisions and changes therefore remain obscure, unexamined, and unimprovable ..read more